Compass Pathways (NASDAQ:CMPS) Upgraded to “Strong-Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Compass Pathways (NASDAQ:CMPS) to a strong-buy rating in a research report report published on Tuesday,Zacks.com reports.

Other equities research analysts also recently issued reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compass Pathways in a report on Monday, April 20th. BTIG Research reissued a “buy” rating and set a $14.00 price objective on shares of Compass Pathways in a research note on Monday, April 20th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 target price on shares of Compass Pathways in a research note on Tuesday, April 28th. B. Riley Financial began coverage on Compass Pathways in a report on Friday, April 24th. They issued a “buy” rating and a $17.00 price target for the company. Finally, Lifesci Capital raised Compass Pathways to a “strong-buy” rating in a research note on Thursday, February 12th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Compass Pathways presently has an average rating of “Moderate Buy” and a consensus target price of $20.45.

Compass Pathways Stock Performance

NASDAQ CMPS opened at $9.32 on Tuesday. The company has a quick ratio of 0.77, a current ratio of 0.77 and a debt-to-equity ratio of 0.55. Compass Pathways has a fifty-two week low of $2.25 and a fifty-two week high of $10.21. The business has a fifty day moving average of $6.80 and a 200-day moving average of $6.54. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -3.02 and a beta of 2.39.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings data on Tuesday, March 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.59). As a group, analysts predict that Compass Pathways will post -1.83 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Compass Pathways

Institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada raised its stake in Compass Pathways by 49.8% during the first quarter. Royal Bank of Canada now owns 89,446 shares of the company’s stock worth $256,000 after purchasing an additional 29,733 shares during the period. Acadian Asset Management LLC grew its stake in shares of Compass Pathways by 42.0% during the 1st quarter. Acadian Asset Management LLC now owns 240,591 shares of the company’s stock valued at $686,000 after buying an additional 71,112 shares during the period. Nantahala Capital Management LLC increased its holdings in shares of Compass Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after buying an additional 1,350,698 shares during the last quarter. Balyasny Asset Management L.P. raised its position in shares of Compass Pathways by 38.0% in the 2nd quarter. Balyasny Asset Management L.P. now owns 854,840 shares of the company’s stock worth $2,394,000 after buying an additional 235,345 shares during the period. Finally, Northeast Financial Consultants Inc purchased a new position in shares of Compass Pathways in the 2nd quarter worth $59,000. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.